<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02515630</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-352-1672</org_study_id>
    <nct_id>NCT02515630</nct_id>
  </id_info>
  <brief_title>Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)</brief_title>
  <official_title>A Phase 2, Open-label, Translational Biology Study of Momelotinib in Transfusion-Dependent Subjects With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the transfusion independence response rate in transfusion-dependent
      adults with myelofibrosis after treatment with momelotinib (MMB).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 29, 2016</start_date>
  <completion_date type="Actual">August 15, 2017</completion_date>
  <primary_completion_date type="Actual">July 18, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Transfusion independence response rate by Week 24</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Transfusion independence response rate is defined as becoming transfusion independent for ≥ 12 weeks at any time on study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Transfusion response rate by Week 24</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Transfusion response rate is defined as becoming not transfusion dependent for ≥ 8 weeks at any time on study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline and change in marker of anemia</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pharmacodynamics biomarker</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Splenic response rate at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>Splenic response rate is defined as ≥ 35% reduction in spleen volume from baseline as measured by MRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate in total symptom score (TSS) at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>Response rate in TSS is defined as achieving a ≥ 50% reduction from baseline in TSS as measured by the modified Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPNSAF TSS) diary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of MMB</measure>
    <time_frame>Predose and 2, 4, 6, hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Last observable concentration (Clast) of MMB</measure>
    <time_frame>Predose and 2, 4, 6, hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed drug concentration at the end of the dosing interval (Ctau) for MMB</measure>
    <time_frame>Predose and 2, 4, 6, hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve from time zero to time of the last quantifiable concentration (AUClast) for MMB</measure>
    <time_frame>Predose and 2, 4, 6, hours postdose</time_frame>
    <description>AUClast is defined as the concentration of drug from time zero to the last quantifiable concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in circulating cytokine and inflammatory markers</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Primary Myelofibrosis (PMF)</condition>
  <condition>Post-polycythemia Vera (Post-PV) Myelofibrosis</condition>
  <condition>Postessential Thrombocythemia (Post-ET) Myelofibrosis</condition>
  <arm_group>
    <arm_group_label>Momelotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MMB for 24 weeks (± 7 days)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MMB</intervention_name>
    <description>Momelotinib (MMB) tablet administered orally once daily</description>
    <arm_group_label>Momelotinib</arm_group_label>
    <other_name>GS-0387</other_name>
    <other_name>CYT387</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Diagnosis of PMF or Post PV/ET-MF

          -  Requires myelofibrosis therapy, in the opinion of the investigator

          -  High risk OR intermediate-2 risk defined by dynamic international prognostic scoring
             system (DIPSS) OR intermediate-1 risk defined by DIPSS and associated with symptomatic
             splenomegaly and/or hepatomegaly

          -  Transfusion dependent at baseline, defined as ≥ 4 U red blood cell (RBC) transfusion
             in the 8 weeks prior to first dose of MMB

          -  Acceptable organ function as evidenced by the following:

               -  Platelet Count ≥ 50 x 10^9/L

               -  Aspartate aminotransferase (AST/SGOT) and alanine aminotransferase (ALT/SGPT) ≤ 3
                  x upper limit of normal (ULN) or AST or ALT ≤ 5 x ULN if liver is involved by
                  disease process as judged by the investigator

               -  Serum creatinine ≤ 2.0 mg/dL or calculated creatinine clearance of ≥ 60 mL/min

               -  Direct bilirubin ≤ 2.0 x ULN

          -  Life expectancy of &gt; 24 weeks

          -  Males and females of childbearing potential who engage in heterosexual intercourse
             must agree to use protocol specified method(s) of contraception

          -  Lactating females must agree to discontinue nursing before MMB administration

          -  Able to understand and willing to sign the informed consent form

        Key Exclusion Criteria:

          -  Prior splenectomy

          -  Splenic irradiation within 3 months prior to the first dose of MMB

          -  Prior treatment with MMB

          -  Known positive status of human immunodeficiency virus (HIV)

          -  Chronic active or acute viral hepatitis A, B, or C infection (testing required for
             hepatitis B and C), or hepatitis B or C carrier

          -  Use of strong cytochrome P450 3A4 (CYP3A4) inducer within 2 weeks prior to the first
             dose of MMB

          -  Uncontrolled intercurrent illness per protocol

          -  Treatment with a Janus kinase (JAK) inhibitor within 21 days of the planned first dose
             of MMB

          -  Presence of peripheral neuropathy ≥ Common Terminology Criteria for Adverse Events
             (CTCAE) Grade 2

          -  Unwilling or unable to undergo a MRI per requirements in the study protocol

          -  Unwilling to consent to genomics sampling

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orange</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>The Bronx</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2015</study_first_submitted>
  <study_first_submitted_qc>August 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2015</study_first_posted>
  <last_update_submitted>August 22, 2017</last_update_submitted>
  <last_update_submitted_qc>August 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primary Myelofibrosis</mesh_term>
    <mesh_term>Polycythemia</mesh_term>
    <mesh_term>Polycythemia Vera</mesh_term>
    <mesh_term>Thrombocytosis</mesh_term>
    <mesh_term>Thrombocythemia, Essential</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

